查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830652

輔助生殖技術市場（按技術、週期類型、治療、最終用戶和產品分類）—2025-2032 年全球預測

Assisted Reproductive Technology Market by Technique, Cycle Type, Treatment, End User, Product - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年輔助生殖技術市場規模將成長至 1,115.1 億美元，複合年成長率為 18.07%。

主要市場統計數據
基準年2024年 295.2億美元
預計2025年 347.6億美元
預測年份：2032年 1115.1億美元
複合年成長率（%） 18.07%

塑造輔助生殖技術服務和相關人員優先事項的臨床、營運和商業性動態的簡明策略框架

輔助生殖技術正在快速發展，相關人員需要重新思考關於臨床實踐、商業模式和病人歷程的假設。新的檢測技術、不斷擴展的醫療服務網路以及不斷變化的患者期​​望正在共同重塑醫療服務。因此，臨床、診斷、設備和相關服務領域的領導者必須綜合考慮醫療、監管和商業性訊號，才能做出及時、基於證據的決策。

本執行摘要概述了影響醫療保健提供者、產品開發者、付款人和投資者的核心動態。它重點關注臨床程序分佈、治療途徑的細微差別、產品和服務差異化以及最終用戶的採用模式。它以技術、週期類型、治療方式、最終用戶和產品線為框架，提供了一個連貫的觀點，探討臨床進展和系統層面的力量如何相互作用，從而創造新的機會和營運挑戰。其目的是提供一個策略視角，以支持在不確定性下進行決策，同時展示哪些短期行動可以帶來重大價值。

科學突破、業務整合和數位創新如何重塑輔助生殖技術的臨床路徑和商業模式

在科學創新、營運整合和以病人為中心的護理模式的推動下，輔助生殖技術領域正在經歷一場變革性的轉變。基因檢測和胚胎選擇方法的進步正在最佳化臨床路徑，降低週期變異性，並提升術前診斷的重要性。同時，實驗室自動化和冷凍保存化學技術的進步使診所能夠簡化流程，並提高治療之間的可重複性。

在營運方面，生育服務提供者之間的整合以及門診手術中心與醫院系統之間合作的加強，正在創造新的轉診模式和規模優勢。私募股權和策略投資者持續重塑市場，推動護理通訊協定的標準化和實驗室服務的集中化。同時，數位健康平台正在簡化患者入院、遠端監控和數據採集流程，幫助診所提高依從性和臨床療效。監管監督和付款人參與正在適應這些變化，強調品質指標、真實世界證據和成本效益。

評估近期關稅變化和貿易動態如何再形成輔助生殖技術供應鏈的採購、製造足跡和成本管理策略

不斷變化的關稅政策和國際貿易動態正在對輔助生殖技術組件和設備的供應鏈產生累積影響。進口關稅影響專用檢測設備、顯微鏡、培養箱和冷凍保存系統的到岸成本，而試劑和培養基的關稅則影響診所和中心實驗室的經常性運作成本。因此，採購實務正在轉向多元化籌資策略，並更加重視與具有彈性物流能力的供應商建立夥伴關係。

製造商和服務供應商正在透過重新評估其生產基地、提高關鍵零件的本地化程度以及協商包含關稅意外事件的供應合約來應對這一挑戰。診所和實驗室正在修改其融資時間表，並尋求靈活的資金籌措結構以緩解短期成本上漲。此外，一些相關人員正在加快對國內製造或區域配送中心的投資，以降低跨境關稅波動帶來的風險。總的來說，這些調整措施將緩解短期營運中斷，但要在維持醫療品質的同時控制成本，需要採購、臨床領導層和商業策略之間進行更長期的協調。

利用多方面的細分，優先考慮技術、週期類型、療法、最終用戶和產品類型的產品開發、臨床支援和商業性方法

基於細分市場的深入分析揭示了臨床技術、週期類型、治療方式、最終用戶環境和產品類型各自構成不同的商業性需求和應用障礙。配子輸卵管植入、體外受精、卵細胞質內單一精蟲顯微注射術、子宮內人工授精和受精卵輸卵管植入等技術在資源強度、技術人員技能需求和實驗室基礎設施需求方面各不相同。就週期類型而言，新鮮供體、新鮮非供體和冷凍保存方法之間的差異會影響治療時間、冷凍保存需求和患者諮詢優先級，從而促使診所製定差異化的運作方案。

對冷凍保存、胚胎移植、基因檢測和卵子等治療類別進行評估，可以發現專業化和捆綁服務的機會。最終使用者環境（包括門診手術中心、生育診所和醫院）呈現不同的資本結構、法律規範和病患吞吐量限制，這些都會影響新設備和耗材的投資週期。最後，將產品細分為耗材、設備、培養基和試劑以及服務，可以揭示不同的利潤狀況和創新方向。耗材和培養基需要頻繁補貨和遵守法規，而設備和服務則代表高額投資，部署週期很長。總之，這些細分使相關人員能夠優先考慮產品開發、確定商業化策略並客製化臨床支援模型，以最大限度地提高臨床價值和營運效率。

美洲、中東和非洲以及亞太地區的法規環境、臨床專業知識分佈和病患需求模式如何創造差異化機會

區域動態顯著影響輔助生殖技術的臨床實務模式、投資意願和監管趨勢。美洲擁有豐富的公私醫療資金、競爭激烈的診所網路、強勁的患者需求以及充滿活力的風險投資支持的創新格局，專業實驗室能力集中在都市區。歐洲、中東和非洲的管理體制和報銷框架各不相同，影響市場進入以及先進診斷和實驗室自動化的採用曲線。跨境合作和醫療旅遊也會影響專業服務的提供地點。亞太地區的特點是產能擴張迅速、臨床專業化程度不斷提高以及監管成熟度參差不齊，這為能夠適應當地臨床工作流程和價格敏感度的國內供應商和跨國公司創造了機會。

這些區域差異直接影響供應鏈設計、商業性夥伴關係和臨床培訓計畫。開發商和服務供應商在製定特定區域的價值提案時，必須兼顧不同的認證要求、進口法規和付款人期望。此外，不同區域的患者偏好和文化因素會影響對週期類型和治療方式的需求，進而影響診所建立護理路徑和與患者互動的策略。因此，有效的區域規劃，結合監管遠見、本地夥伴關係和適應文化的患者支持，可以加速採用並維持長期臨床效果。

透過產品可靠性、整合臨床工作流程和服務主導的實施策略來定義競爭動態，以加速不孕症護理領域的技術接受度

輔助生殖技術生態系統中各公司之間的競爭動態反映了臨床可靠性、產品創新和策略服務夥伴關係之間的平衡。領先的儀器製造商和實驗室解決方案提供商在可靠性、易用性和降低實驗室差異性的整合工作流程方面各有千秋。耗材和培養基供應商則在配方穩定性、法規遵循性和供應連續性方面競爭。服務型公司擴大將培訓、遠端監控和實驗室品質保證捆綁在一起，以支援診所的採用並降低其擴大病例量的營運風險。

臨床醫生與商業團隊之間的策略合作仍然是產品改進的關鍵驅動力。早期採用者可作為檢驗新方法的參考點，而其他採用者則透過與門診手術中心和醫院系統的合作實現規模化，將技術嵌入現有的護理路徑中。最有效的市場參與企業將結合卓越的技術、強大的售後支援、明確的監管立場，以及展示工作流程效率的能力，從而為醫療服務提供者帶來可衡量的臨床或經濟效益。

為企業提供實際的策略行動，以加強臨床夥伴關係、供應彈性、整合產品和區域上市效率

產業領導者應採取一系列重點行動，在維護臨床誠信和病患療效的同時，確保競爭優勢。首先，優先與高績效診所夥伴關係，共同製定方案並產生真實世界證據，以強化產品價值提案。透過使產品開發週期與臨床醫生的需求保持一致，公司可以縮短產品上市時間，並增強臨床醫生對新治療方法的信心。其次，投資於供應鏈彈性以及區域製造和分銷能力，可以減輕貿易中斷和關稅變化的影響，並保護淨利率和服務連續性。

第三，採用整合的商業模式，將器械、耗材和臨床導向服務（例如培訓和品管）結合起來，創建捆綁產品，簡化最終用戶的採購和上線流程。第四，調整區域市場策略，以反映當地的監管、文化和付款人環境，使定價、報銷支援和病患溝通與市場實際情況相符。最後，投入資源用於數位化賦能，例如病人參與平台、遠端監控和數據分析，以提高依從性、最佳化吞吐量，並產生縱向證據來支持臨床和經濟價值主張。這些措施共同作用，使組織能夠靈活應對市場變化，並充分利用臨床和營運方面的進步。

這些見解背後的調查方法結合了對臨床文獻、監管文件和公開指南的結構化綜述，以及對臨床醫生、實驗室主任和公司高管的定性訪談。證據綜合研究優先考慮高品質的臨床研究、專業協會共識聲明和監管趨勢文件，以確保結論反映當前的實踐模式和管治預期。訪談資料用於檢驗營運假設、了解採購行為，並揭示正式出版物中可能尚未涵蓋的新興產品偏好。

分析方法包括對技術、週期類型、療法、最終用戶和產品細分進行比較評估，以揭示差異化的促進因素和應用障礙。區域分析納入了監管影響、報銷細則和容量指標，以闡明商業性影響。自始至終，我們專注於將來自文獻資訊來源的定量訊號與領域專家的定性觀察相結合，以形成可行的觀點，同時承認持續存在的不確定性領域以及持續證據監測的必要性。

整合臨床、營運和商業性需求，以確定不斷發展的輔助生殖技術生態系統中的永續競爭優勢

總而言之，輔助生殖技術正處於曲折點，臨床創新、操作複雜度和市場動態正在匯聚，從而催生出差異化的贏家。特定技術需求、週期類型偏好、治療方式、最終用戶能力和產品定位的相互作用，將決定誰能在市場發展過程中獲得價值。積極主動地將臨床證據產生與彈性供應策略和整合服務模式結合的相關人員，將最有能力在負責任地擴展業務的同時，提供一致的成果。

因此，決策者應優先考慮能夠加速真實世界檢驗的夥伴關係，投資於區域供應的連續性，並採用能夠簡化供應商採用的商業性方法。透過專注於這些優先事項，醫療保健組織可以改善患者照護，並在臨床可靠性和卓越營運至關重要的領域建立可辯護的商業性提案。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 擴大採用胚胎著床前基因檢測來評估胚胎健康並制定個人化移植策略
  • 擴展家用生育監測套件，利用人工智慧驅動的荷爾蒙追蹤進行早期療育
  • 整合區塊鏈技術，確保病患資料安全並簡化跨境卵子捐贈流程
  • 在為職業發展而推遲生育的專業人士中，社會卵子冷凍服務日益增多
  • 生育診所和遠端醫療平台擴大合作提供虛擬諮詢和遠距支持
  • 利用延時成像和AI預測分析來評估胚胎活力的非侵入性評估技術開發
  • 男性不孕症治療激增，包括基因編輯研究和針對精子發生的分子診斷
  • 透過公私合營和行動診所部署，在新興市場擴大低成本 IVF 服務
  • 人們對為腫瘤患者整合新型冷凍保存介質和方法的生育力保存通訊協定的興趣日益濃厚。
  • 推出數位健康平台，為整個輔助生殖週期提供個人化生育指導和情感支持

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 輔助生殖科技市場（依技術）

  • 配子輸卵管植入
  • 體外受精
    • 新捐款者
    • 新的非捐贈者
    • 冷凍
  • 卵細胞質內單一精蟲顯微注射術
  • 子宮內人工授精
  • 受精卵輸卵管內移植

9. 輔助生殖技術市場（依週期類型）

  • 新捐款者
  • 新的非捐贈者
  • 冷凍

第10章輔助生殖科技市場（依治療）

  • 冷凍保存
  • 胚胎移植
  • 基因檢測
  • 卵子收集

第 11 章輔助生殖技術市場（按最終用戶分類）

  • 門診手術中心
  • 不孕不育診所
  • 醫院

第12章輔助生殖技術市場（按產品）

  • 耗材
  • 裝置
  • 培養基和試劑
  • 服務

第 13 章：輔助生殖科技市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章輔助生殖技術市場（按群體）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國輔助生殖技術市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Merck KGaA
    • Thermo Fisher Scientific Inc.
    • CooperCompanies, Inc.
    • Vitrolife AB
    • FUJIFILM Irvine Scientific, Inc.
    • Charles River Laboratories International, Inc.
    • Progyny, Inc.
    • Hamilton Thorne Ltd.
    • Ovascience, Inc.
    • Cryo-Cell International, Inc.
Product Code: MRR-436901065A94

The Assisted Reproductive Technology Market is projected to grow by USD 111.51 billion at a CAGR of 18.07% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 29.52 billion
Estimated Year [2025] USD 34.76 billion
Forecast Year [2032] USD 111.51 billion
CAGR (%) 18.07%

Concise strategic framing of clinical, operational, and commercial dynamics reshaping assisted reproductive technology services and stakeholder priorities

Assisted reproductive technology is evolving at a pace that requires stakeholders to revisit assumptions about clinical practice, commercial models, and patient journeys. Emerging laboratory techniques, expanding provider networks, and shifting patient expectations are converging to reshape care delivery. As a result, leaders across clinical, diagnostic, equipment, and adjacent service segments must synthesize medical, regulatory, and commercial signals to make timely, evidence-based decisions.

This executive summary synthesizes core dynamics affecting practitioners, product developers, payers, and investors. It focuses on clinical technique distribution, treatment pathway nuances, product and service differentiation, and end-user adoption patterns. By framing the discussion around technique, cycle type, treatment modality, end-user, and product lines, the narrative offers a cohesive perspective on how clinical advances and system-level forces are interacting to create new opportunities and operational challenges. The aim is to provide a strategic lens that supports decision-making under uncertainty, while signalling where near-term action can deliver outsized value.

How scientific breakthroughs, operational consolidation, and digital innovations are jointly reshaping clinical pathways and commercial models in assisted reproduction

The landscape of assisted reproductive technology is experiencing transformative shifts driven by scientific innovation, operational consolidation, and patient-centric care models. Advances in genetic testing and embryo selection methods are refining clinical pathways, reducing cycle variability, and increasing the emphasis on pre-procedural diagnostics. Concurrently, laboratory automation and improvements in cryopreservation chemistry are enabling clinics to streamline throughput and enhance reproducibility across treatments.

Operationally, consolidation among fertility providers and increased collaboration between ambulatory surgical centers and hospital systems are creating new referral patterns and scale advantages. Private equity and strategic investors continue to reshape the marketplace, prompting standardization of care protocols and the emergence of centralized laboratory services. In parallel, digital health platforms are simplifying patient onboarding, remote monitoring, and data capture, which is helping clinics improve adherence and clinical outcomes. Regulatory scrutiny and payer engagement are adapting to these changes, emphasizing quality metrics, real-world evidence, and cost-effectiveness, which collectively alter how new technologies are adopted and reimbursed.

Assessment of how recent tariff changes and trade dynamics are reshaping procurement, manufacturing footprints, and cost management strategies across the assisted reproduction supply chain

Tariff policy changes and international trade dynamics are exerting cumulative effects on the supply chain for assisted reproductive technology components and equipment. Import duties can influence the landed cost of specialized laboratory equipment, microscopes, incubators, and cryogenic storage systems, while tariffs on reagents and media affect recurring operational expenditures for clinics and centralized labs. As a consequence, procurement practices are shifting toward diversified sourcing strategies and increased emphasis on vendor partnerships with resilient logistics capabilities.

Manufacturers and service providers are responding by re-evaluating production footprints, increasing localization of critical components, and negotiating supply contracts that incorporate tariff contingencies. Clinics and laboratories are reassessing capital acquisition timelines and exploring flexible financing structures to mitigate near-term cost escalations. In addition, some stakeholders are accelerating investments in domestic manufacturing or regional distribution hubs to reduce exposure to cross-border tariff volatility. These adaptive measures collectively dampen immediate operational disruption but require longer-term alignment between procurement, clinical leadership, and commercial strategy to sustain cost control while preserving quality of care.

Leveraging multidimensional segmentation to prioritize product development, clinical support, and commercial approaches across technique, cycle type, treatment, end user, and product categories

Insightful segmentation-based analysis illuminates how clinical techniques, cycle types, treatment modalities, end-user settings, and product categories each drive distinct commercial imperatives and adoption barriers. Across techniques such as gamete intrafallopian transfer, in vitro fertilization, intracytoplasmic sperm injection, intrauterine insemination, and zygote intrafallopian transfer, practices vary in resource intensity, technician skill requirements, and laboratory infrastructure needs, with in vitro fertilization representing a focal point given its procedural complexity and breadth of clinical pathways that include fresh donor, fresh non-donor, and frozen cycles. Considering cycle type, the distinctions among fresh donor, fresh non-donor, and frozen approaches influence scheduling, cryostorage demand, and patient counseling priorities, prompting clinics to develop differentiated operational playbooks.

When evaluated through the lens of treatment categories such as cryopreservation, embryo transfer, genetic testing, and oocyte retrieval, opportunities for specialization and service bundling become apparent, particularly where genetic testing can be integrated early in the patient journey to inform downstream clinical decisions. End-user environments-spanning ambulatory surgical centers, fertility clinics, and hospitals-present varying capital structures, regulatory oversight, and patient throughput constraints that affect investment cycles for new equipment and consumables. Lastly, product segmentation into consumables, equipment, media and reagents, and services highlights divergent margin profiles and innovation vectors; consumables and media demand frequent replenishment and regulatory compliance, whereas equipment and services represent higher-ticket investments with extended adoption timelines. Taken together, these segmentation dimensions enable stakeholders to prioritize product development, target commercialization strategies, and tailor clinical support models to maximize clinical value and operational efficiency.

How regional regulatory environments, clinical expertise distribution, and patient demand patterns create differentiated opportunities across Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics are materially shaping clinical practice patterns, investment appetite, and regulatory trajectories in assisted reproductive technologies. In the Americas, a mix of private and public healthcare funding drives competitive clinic networks, strong patient demand, and active venture-backed innovation, with urban centers concentrating specialized laboratory capabilities. Europe, Middle East & Africa displays heterogenous regulatory regimes and reimbursement frameworks that influence market entry and the adoption curve for advanced diagnostics and laboratory automation; cross-border collaboration and medical tourism also affect where specialized services are delivered. Asia-Pacific is characterized by rapid capacity expansion, rising clinical expertise, and varying levels of regulatory maturity, creating opportunities for both domestic suppliers and multinational firms that can adapt to local clinical workflows and price sensitivities.

These regional distinctions have direct implications for supply chain design, commercial partnerships, and clinical training programs. Manufacturers and service providers must navigate distinct certification requirements, import regulations, and payer expectations while developing localized value propositions. Moreover, regional patient preferences and cultural considerations shape demand for cycle types and treatment modalities, which in turn influence how clinics structure care pathways and patient engagement strategies. Effective regional plans therefore combine regulatory foresight, local partnerships, and culturally attuned patient support to accelerate adoption and sustain long-term clinical outcomes.

Competitive dynamics defined by product reliability, integrated clinical workflows, and service-led adoption strategies that accelerate technology acceptance in fertility care

Competitive dynamics among companies operating in the assisted reproductive technology ecosystem reflect a balance between clinical credibility, product innovation, and strategic service partnerships. Leading equipment manufacturers and laboratory solution providers differentiate through reliability, ease of use, and integrated workflows that reduce laboratory variability. Consumable and media suppliers compete on formulation stability, regulatory compliance, and supply continuity, as reproducible performance directly affects clinical outcomes. Service-oriented firms are increasingly bundling training, remote monitoring, and laboratory quality assurance to support adoption and mitigate operational risk for clinics expanding their case volumes.

Strategic collaboration between clinicians and commercial teams continues to be a major driver of product refinement, with early adopters serving as reference sites that validate new approaches. Meanwhile, some companies are scaling through partnerships with ambulatory surgical centers and hospital systems to embed technology into established care pathways. The most effective market participants combine technical excellence with robust post-sale support, clear regulatory positioning, and an ability to demonstrate workflow efficiencies that translate into measurable clinical or economic benefits for provider organizations.

Practical strategic actions for companies to enhance clinical partnership, supply resilience, integrated offerings, and regional go-to-market effectiveness

Industry leaders should pursue a focused set of actions to secure competitive advantage while preserving clinical integrity and patient outcomes. First, prioritize partnerships with high-performing clinics to co-develop protocols and to generate real-world evidence that reinforces product value propositions. By aligning product development cycles with clinician needs, companies can reduce time-to-adoption and increase practitioner confidence in new modalities. Second, invest in supply chain resilience and regional manufacturing or distribution arrangements to mitigate the effects of trade disruptions and tariff shifts, thereby protecting margins and service continuity.

Third, adopt integrated commercial models that combine equipment, consumables, and clinically oriented services such as training and quality management to create bundled offerings that simplify procurement and operational onboarding for end users. Fourth, tailor regional go-to-market strategies that reflect local regulatory, cultural, and payer environments, ensuring that pricing, reimbursement support, and patient communication are aligned with market realities. Finally, commit resources to digital enablement-patient engagement platforms, remote monitoring, and data analytics-to improve adherence, optimize throughput, and generate longitudinal evidence that supports both clinical and economic value claims. Collectively, these actions position organizations to respond nimbly to market shifts and to capitalize on clinical and operational advancements.

The research methodology underpinning these insights combines a structured review of clinical literature, regulatory materials, and publicly available guidance with qualitative interviews of clinicians, laboratory directors, and commercial executives. Evidence synthesis prioritized high-quality clinical studies, consensus statements from professional societies, and documentation of regulatory trends to ensure conclusions reflect current practice patterns and governance expectations. Interview data were used to validate operational assumptions, understand procurement behaviors, and surface emerging product preferences that may not yet be captured in formal publications.

Analytical approaches included comparative assessment across technique, cycle type, treatment, end-user, and product segmentation to reveal differentiation drivers and adoption barriers. Regional analysis incorporated regulatory pathways, reimbursement nuances, and capacity indicators to contextualize commercial implications. Throughout, emphasis was placed on triangulation-aligning quantitative signals from documented sources with qualitative observations from field experts-to produce actionable perspectives while acknowledging areas of ongoing uncertainty and the need for continuous evidence monitoring.

Synthesis of clinical, operational, and commercial imperatives that will determine sustainable competitive advantage in the evolving assisted reproductive technology ecosystem

In conclusion, assisted reproductive technology is at an inflection point where clinical innovation, operational sophistication, and market dynamics converge to create differentiated winners. The interplay between technique-specific demands, cycle type preferences, treatment modalities, end-user capabilities, and product positioning will determine who captures value as the market evolves. Stakeholders that proactively align clinical evidence generation with resilient supply strategies and integrated service models will be best positioned to deliver consistent outcomes while scaling responsibly.

Decision-makers should therefore prioritize partnerships that accelerate real-world validation, invest in regional supply continuity, and adopt commercial approaches that simplify adoption for providers. By focusing on these priorities, organizations can both improve patient care and establish defensible commercial propositions in a sector where clinical credibility and operational excellence are essential.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of preimplantation genetic testing for embryo health assessment and personalized transfer strategies
  • 5.2. Expansion of at-home fertility monitoring kits leveraging AI-driven hormone tracking for early intervention
  • 5.3. Integration of blockchain technology to secure patient data and streamline cross-border egg donation processes
  • 5.4. Growth in social egg freezing services among working professionals delaying parenthood for career progression
  • 5.5. Rising collaborations between fertility clinics and telemedicine platforms to offer virtual consultations and remote support
  • 5.6. Development of noninvasive embryo evaluation techniques using time-lapse imaging and AI predictive analytics for viability scoring
  • 5.7. Surge in male fertility treatments incorporating gene editing research and targeted molecular diagnostics for spermatogenesis
  • 5.8. Expansion of low-cost IVF services in emerging markets through public-private partnerships and mobile clinic deployments
  • 5.9. Increasing focus on fertility preservation protocols for oncology patients integrating novel cryopreservation media and methods
  • 5.10. Adoption of digital health platforms for personalized fertility coaching and emotional support throughout assisted reproduction cycles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Assisted Reproductive Technology Market, by Technique

  • 8.1. Gamete Intrafallopian Transfer
  • 8.2. In Vitro Fertilization
    • 8.2.1. Fresh Donor
    • 8.2.2. Fresh Non-Donor
    • 8.2.3. Frozen
  • 8.3. Intracytoplasmic Sperm Injection
  • 8.4. Intrauterine Insemination
  • 8.5. Zygote Intrafallopian Transfer

9. Assisted Reproductive Technology Market, by Cycle Type

  • 9.1. Fresh Donor
  • 9.2. Fresh Non-Donor
  • 9.3. Frozen

10. Assisted Reproductive Technology Market, by Treatment

  • 10.1. Cryopreservation
  • 10.2. Embryo Transfer
  • 10.3. Genetic Testing
  • 10.4. Oocyte Retrieval

11. Assisted Reproductive Technology Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Fertility Clinics
  • 11.3. Hospitals

12. Assisted Reproductive Technology Market, by Product

  • 12.1. Consumables
  • 12.2. Equipment
  • 12.3. Media And Reagents
  • 12.4. Services

13. Assisted Reproductive Technology Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Assisted Reproductive Technology Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Assisted Reproductive Technology Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck KGaA
    • 16.3.2. Thermo Fisher Scientific Inc.
    • 16.3.3. CooperCompanies, Inc.
    • 16.3.4. Vitrolife AB
    • 16.3.5. FUJIFILM Irvine Scientific, Inc.
    • 16.3.6. Charles River Laboratories International, Inc.
    • 16.3.7. Progyny, Inc.
    • 16.3.8. Hamilton Thorne Ltd.
    • 16.3.9. Ovascience, Inc.
    • 16.3.10. Cryo-Cell International, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ZYGOTE INTRAFALLOPIAN TRANSFER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ZYGOTE INTRAFALLOPIAN TRANSFER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ZYGOTE INTRAFALLOPIAN TRANSFER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ZYGOTE INTRAFALLOPIAN TRANSFER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ZYGOTE INTRAFALLOPIAN TRANSFER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ZYGOTE INTRAFALLOPIAN TRANSFER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CRYOPRESERVATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CRYOPRESERVATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CRYOPRESERVATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CRYOPRESERVATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EMBRYO TRANSFER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EMBRYO TRANSFER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EMBRYO TRANSFER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EMBRYO TRANSFER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EMBRYO TRANSFER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EMBRYO TRANSFER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OOCYTE RETRIEVAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OOCYTE RETRIEVAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OOCYTE RETRIEVAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OOCYTE RETRIEVAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OOCYTE RETRIEVAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OOCYTE RETRIEVAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY MEDIA AND REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY MEDIA AND REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY MEDIA AND REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY MEDIA AND REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY MEDIA AND REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY MEDIA AND REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 279. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 282. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 283. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 284. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 285. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 288. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 289. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 292. G